Dermatology play Dermira files for IPO

Dermira Inc. (Redwood City, Calif.) filed to raise up to $75 million in an IPO on NASDAQ underwritten by Citigroup; Leerink; Guggenheim Securities; and Needham. Dermira said partner UCB Group (Euronext:UCB) may purchase about $7.5 million of stock in the offering.

Dermira's topical small molecule anticholinergic DRM04 is in Phase IIb testing to treat hyperhidrosis (excessive sweating), with data expected next half. Also next half, the company plans to start a Phase IIb study of topical small molecule sebum inhibitor DRM01 to treat acne. ...